81 related articles for article (PubMed ID: 26781796)
1. Overexpression of C35 in breast carcinomas is associated with tumor progression and lymphnode metastasis.
Yin K; Ba Z; Li C; Xu C; Zhao G; Zhu S; Yan G
Biosci Trends; 2015 Dec; 9(6):386-92. PubMed ID: 26781796
[TBL] [Abstract][Full Text] [Related]
2. C35 is overexpressed in colorectal cancer and is associated tumor invasion and metastasis.
Dong X; Huang Y; Kong L; Li J; Kou J; Yin L; Yang J
Biosci Trends; 2015 Apr; 9(2):117-21. PubMed ID: 26173296
[TBL] [Abstract][Full Text] [Related]
3. C35 (C17orf37) is a novel tumor biomarker abundantly expressed in breast cancer.
Evans EE; Henn AD; Jonason A; Paris MJ; Schiffhauer LM; Borrello MA; Smith ES; Sahasrabudhe DM; Zauderer M
Mol Cancer Ther; 2006 Nov; 5(11):2919-30. PubMed ID: 17121940
[TBL] [Abstract][Full Text] [Related]
4. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast.
Hussein MR; Abd-Elwahed SR; Abdulwahed AR
Cell Biol Int; 2008 Jun; 32(6):698-707. PubMed ID: 18296077
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan.
Almasri NM; Al Hamad M
Breast Cancer Res; 2005; 7(5):R598-604. PubMed ID: 16168103
[TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of Bmi-1 in breast cancer].
Feng Y; Song LB; Guo BH; Liao WT; Li MZ; Liu WL; Zeng MS; Zhang L
Ai Zheng; 2007 Feb; 26(2):154-7. PubMed ID: 17298744
[TBL] [Abstract][Full Text] [Related]
7. RACK1: A superior independent predictor for poor clinical outcome in breast cancer.
Cao XX; Xu JD; Liu XL; Xu JW; Wang WJ; Li QQ; Chen Q; Xu ZD; Liu XP
Int J Cancer; 2010 Sep; 127(5):1172-9. PubMed ID: 20020495
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of C35 decreased the cell viability and migration of breast ductal carcinoma cells.
Che W; Bao Y; Tang F
PLoS One; 2017; 12(8):e0183941. PubMed ID: 28859163
[TBL] [Abstract][Full Text] [Related]
10. Invasive micropapillary carcinoma of the breast: a clinicopathologic study of 103 cases of an unusual and highly aggressive variant of breast carcinoma.
Gokce H; Durak MG; Akin MM; Canda T; Balci P; Ellidokuz H; Demirkan B; Gorken IB; Sevinc AI; Kocdor MA; Saydam S; Harmancioglu O
Breast J; 2013; 19(4):374-81. PubMed ID: 23714006
[TBL] [Abstract][Full Text] [Related]
11. [Expression and significance of phosphorylated Girdin in breast cancer].
Xu Y; Fu L; Gu F; Ma YJ
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):205-9. PubMed ID: 22780975
[TBL] [Abstract][Full Text] [Related]
12. Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.
Sharif MA; Mamoon N; Mushtaq S; Khadim MT
J Coll Physicians Surg Pak; 2009 Feb; 19(2):99-103. PubMed ID: 19208313
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
14. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens MR
J Clin Pathol; 2005 Jun; 58(6):611-6. PubMed ID: 15917412
[TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy.
Bartlett JM; Ellis IO; Dowsett M; Mallon EA; Cameron DA; Johnston S; Hall E; A'Hern R; Peckitt C; Bliss JM; Johnson L; Barrett-Lee P; Ellis P
J Clin Oncol; 2007 Oct; 25(28):4423-30. PubMed ID: 17906205
[TBL] [Abstract][Full Text] [Related]
16. [Expression of androgen receptor in breast carcinoma and its relationship with estrogen receptor, progesterone receptor and HER2 status].
Chen J; Zhang X; Tian R; Liu Y; Dong HM; Guo RF; Liang HY
Zhonghua Bing Li Xue Za Zhi; 2010 Nov; 39(11):743-6. PubMed ID: 21215164
[TBL] [Abstract][Full Text] [Related]
17. Correlation between genetic and biological aspects in primary non-metastatic breast cancers and corresponding synchronous axillary lymph node metastasis.
D'Andrea MR; Limiti MR; Bari M; Zambenedetti P; Montagutti A; Ricci F; Pappagallo GL; Sartori D; Vinante O; Mingazzini PL
Breast Cancer Res Treat; 2007 Mar; 101(3):279-84. PubMed ID: 16835704
[TBL] [Abstract][Full Text] [Related]
18. Folate Receptor Alpha Immunohistochemistry in Cytology Specimens of Metastatic Breast Carcinoma.
Sheikh UN; Cohen C; Siddiqui MT
Acta Cytol; 2015; 59(4):298-304. PubMed ID: 26413911
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients.
Nagai MA; Gerhard R; Fregnani JH; Nonogaki S; Rierger RB; Netto MM; Soares FA
Breast Cancer Res Treat; 2011 Feb; 126(1):1-14. PubMed ID: 20369286
[TBL] [Abstract][Full Text] [Related]
20. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]